|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 64-69
Selective Expansion of Primitive Normal Hematopoietic Cells in Cytokine-Supplemented Cultures of Purified Cells From Patients With Chronic Myeloid Leukemia
By
A.L. Petzer,
C.J. Eaves,
M.J. Barnett, and
A.C. Eaves
From the Terry Fox Laboratory and the Division of Hematology, British Columbia Cancer Agency and the Departments of Medical Genetics, Medicine, and Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
 |
ABSTRACT |
We have previously reported that primitive normal hematopoietic cells detectable as long-term culture-initiating cells (Ph-LTC-IC) are present at high levels in the blood of some patients with chronic myeloid leukemia (CML). We now show that this population can be expanded several-fold when highly purified CD34+CD38- cells isolated from the blood of such patients are cultured for 10 days in a serum-free medium containing 100 ng/mL of Flt3-ligand and Steel factor and 20 ng/mL of interleukin-3 (IL-3) and IL-6, and granulocyte colony-stimulating factor. In similar cultures initiated with CD34+CD38- cells from CML blood samples in which all of the LTC-IC were leukemic (Ph+), Ph+ LTC-IC activity was rapidly lost both in the presence and absence of admixed CD34+CD38- cells isolated from normal marrow. Conversely, the ability of normal LTC-IC to expand their numbers was shown to be independent of the presence of Ph+LTC-IC and later types of Ph+colony-forming cell (CFC) progenitors. In contrast to the LTC-IC, CFC were consistently -a m p l i f i e d i n c u l t u r e s i n i t i a t e d w i t h C M L - d e r i v e d -CD34+CD38- cells and the additional CFC present after 10 days were, like the starting population of CFC, almost exclusively Ph+ regardless of the genotype(s) of the LTC-IC in the original CML samples. Amplification of the Ph+CFC population in these cultures showed the same factor dependence as previously demonstrated for the in vitro expansion of CFC from normal marrow CD34+CD38- cells. Ph+LTC-IC disappeared regardless of the cytokines present. Taken together these findings support a model of CML in which the leukemic stem cells are characterized by a decreased probability of self-renewal and an increased probability of differentiation. In addition, they suggest new opportunities for improving the treatment of CML using strategies that require autologous stem cell rescue.
| |
INTRODUCTION |
CHRONIC MYELOID leukemia (CML) is a hematologic malignancy that is believed to arise in a hematopoietic stem cell with lymphoid and myeloid differentiation potential.1 The disease is characterized biologically by the deregulated overgrowth of the marrow by a multilineage clone of cells, all of which are marked by the presence of a novel BCR-ABL fusion gene.2 The formation of this new gene usually involves a reciprocal translocation between the long arms of chromosomes 9 and 22 leading to the formation of a unique chromosome identified as the Philadelphia chromosome (Ph).3 The transcription of the BCR-ABL gene leads to the synthesis of a new protein that has been shown to have transforming properties in a variety of model systems.4-9 In patients, a marked expansion of the leukemic (Ph+) clone is accompanied by an excessive production of mature granulocytes and a concomitant suppression of normal hematopoiesis. Nevertheless, a residual population of primitive normal (Ph-) cells persists in many patients.10-13 These cells may be found in the blood in patients studied soon after diagnosis14 or during the period of endogenous hematopoietic recovery that follows myelo-reductive therapy15 and include cells with functional properties associated with stem cells; ie, cells with transplantable hematopoietic regenerative potential16 and that are able to produce in vitro colony-forming cells (CFC) for at least 5 weeks in cocultures containing adherent stromal cell feeder layers.10,14 The latter are referred to as long-term culture-initiating cells (LTC-IC).17 In addition to Ph-LTC-IC, variable numbers of Ph+LTC-IC are also found in the marrow and blood of CML patients.13,14 However, at all later stages of myeloid differentiation Ph+ cells typically predominate.14,18
Normal and leukemic LTC-IC are not readily distinguished with respect to their expression of most surface markers thus far examined. These include CD34, CD71, CD38, and Thy-1, whose upregulation or downregulation has been associated with a primitive state in analyses of hematopoietic tissues from normal individuals.19-23 Therefore, isolation of various subfractions of the CD34+ cells present in CML blood samples (eg, the CD34+CD71-CD38- subpopulation) can provide a source of cells that is highly enriched in LTC-IC, but their predominant genotype remains the same as in the original unfractionated blood sample and this can be either Ph- or Ph+.14 Even where differences in the relative proportion of leukemic and normal LTC-IC in a given subpopulation have been reported (eg, as in the case of CD34+HLA-DR-cells24,25 ), phenotypic heterogeneity among both types of LTC-IC exists.25,26 Thus, isolation of a particular phenotype may not provide the resolving power necessary to obtain clinically useful CML autografts. An alternative purging approach under current clinical evaluation27,28 is based on the rapid loss of Ph+LTC-IC that is seen when CML blood or marrow cells are cocultured on stroma under conditions that maintain (but do not expand) normal LTC-IC.29 Because we recently found that LTC-IC from normal marrow can be significantly expanded in cultures containing soluble cytokines,23,30 it was of interest to determine whether the Ph-LTC-IC often present in isolates of CML cells could also be expanded under these conditions and, if so, whether this would be accompanied by an increase or decrease in Ph+LTC-IC numbers.
| |
MATERIALS AND METHODS |
Heparinized blood samples were obtained with informed consent from nine CML patients undergoing routine hematologic assessment. (For convenience, patients are referred to by the same number throughout the Tables in the Results.) All had elevated white blood cell (WBC) counts and were at various stages in the course of their disease as described in detail previously.14 Normal cadaveric bone marrow cells were purchased from the Northwest Tissue Co (Seattle, WA) and cryopreserved before use. All procedures for the isolation, cryopreservation, and thawing of light-density (<1.077 g/mL) cells followed by the sorting by fluorescence-activated cell sorting (FACS) of CD34+CD38- populations and their subsequent assessment for Ph+ or Ph-CFC and LTC-IC content before and after culture at 5 × 103 cells/mL in serum-free media (StemCell Technologies Inc, Vancouver, BC, Canada) containing various cytokine supplements were the same as previously described, including the use of a 6-week CFC output on murine fibroblast feeders engineered to produce human interleukin-3 (IL-3), granulocyte colony-stimulating factor (G-CSF), and Steel factor (SF) to measure human LTC-IC.14,23,30,31
| |
RESULTS |
Rapid loss of Ph+LTC-IC activity with expansion of Ph+CFC in serum-free cultures of CD34+CD38- CML cells.
Table 1 shows the results of a first series of experiments to investigate how the number of Ph+LTC-IC (and CFC) might change in cultures of highly purified CD34+CD38- CML cells maintained for 10 days under serum-free conditions in the presence 100 ng/mL of Flt3-ligand (FL) and SF, plus 20 ng/mL of IL-3, IL-6, and G-CSF. This combination of cytokines was used because it had been previously found to stimulate a large expansion of both LTC-IC ( 25-fold) and CFC (800-fold) in analogous cultures of CD34+CD38- cells isolated from normal marrow.30 As shown in Table 1, these conditions supported a rapid expansion of the CFC -p o p u l a t i o n i n c u l t u r e s i n i t i a t e d w i t h e x c l u s i v e l y -Ph+CD34+CD38- cells (although the extent of this expansion was highly variable). Interestingly, in the same 10-day-old CML cultures, Ph+LTC-IC activity was consistently lost (no detectable LTC-IC activity in cultures from three patients, ie, a >1,000-fold decrease, with an 50-fold reduction measured in the fourth case).
Because we had previously found that different cytokine combinations are required to maximize the in vitro expansion of CFC and LTC-IC from normal CD34+CD38- marrow cells,30 the possibility that the various component cytokines, either alone or in other combinations, might have had a different effect on Ph+CD34+CD38- cells was investigated. However, as shown in Table 2, the same rapid loss of Ph+LTC-IC activity seen with the five-cytokine cocktail (Table 1) occurred regardless of the cytokine(s) added. On the other hand, the results for Ph+CFC expansion (Table 3) paralleled those previously obtained for the expansion of CFC in cultures of normal CD34+CD38- marrow cells30; ie, IL-3 was the most effective single cytokine that could stimulate an amplification of the Ph+CFC population, and the combination of FL plus SF and IL-3, although more effective than any one of these three alone, was not as effective as when IL-6 and G-CSF were also present (compare results in Table 3 with those shown in Table 1).
View this table:
[in this window]
[in a new window]
|
Table 2.
Effect of Various Cytokines on the Loss of Leukemic (Ph+) LTC-IC Activity in 10-Day Cultures of CD34+CD38- CML Blood Cells
|
|
Expansion of normal LTC-IC in cultures of CD34+CD38- cells containing various mixtures of Ph+and Ph-LTC-IC and CFC.
Experiments were then performed to determine whether an expansion of the normal (Ph-) LTC-IC seen in some CML blood samples14 could be obtained under conditions that had been found to cause a rapid decrease in detectable Ph+LTC-IC (Table 1). To investigate this question, we used a different set of five cryopreserved CML blood cell samples in which the LTC-IC had been previously found to be predominantly Ph- (only Ph-LTC-IC detected), although the coexisting CFC were exclusively Ph+. The numbers and genotypes of the LTC-IC and CFC obtained from 10-day suspension cultures initiated with the CD34+CD38- cells isolated from these samples are shown in Tables 4 and 5, respectively. All of these cultures contained the same five-cytokine cocktail used in the experiments described in Table 1 (100 ng/mL of FL and SF, and 20 ng/mL of IL-3, IL-6, and G-CSF). In two cases (nos. 6 and 7), the Ph-LTC-IC had increased fourfold to fivefold by the end of the 10-day culture period. In the third case (no. 5), a fivefold increase in Ph-LTC-IC was obtained in a first experiment but not in a repeat experiment in which the initial yield of LTC-IC was considerably lower. In the fourth case (no. 8), the Ph-LTC-IC declined slightly and, in the fifth case (no. 9), where again the LTC-IC content of the starting population of CD34+CD38-cells was unusually low, their numbers were not sustained. CFC numbers were expanded in all cultures and, unexpectedly, in every case, were predominantly Ph+ (Table 5). The fact that this occurred in the absence of detectable Ph+LTC-IC indicates that the new CFC present in such 10-day cultures were derived either from CD34+CD38- cells initially detectable as CFC and/or from some otherwise uncharacterized CD34+CD38- cell type that is not detectable as either a CFC or as an LTC-IC. The fact that very few Ph-CFC were produced in cultures that contained exclusively Ph-LTC-IC suggests that the majority of the expanded populations of CFC obtained within the first 10 days in cultures of normal CD34+CD38- cells30 also represent the progeny of cells that are not initially detectable as LTC-IC. However, in neither instance do these findings exclude the possibility that many (or even most) normal or Ph+LTC-IC can give rise to small numbers of CFC within 10 days under these culture conditions because such cells would represent a population too small to be detected by the level of discrimination possible by cytogenetic analysis of individual colonies.
To determine whether the different responses exhibited by Ph+ and Ph- progenitors in cultures of CD34+CD38- CML blood cells might be influenced by potential interactions between Ph+ and Ph- cells, a series of mixing experiments was performed. In each of these, cultures were initiated with Ph+CD34+CD38- cells isolated from different CML blood samples and then mixed with an equal number of CD34+CD38- cells obtained from a sample of marrow from a normal individual. For these experiments, additional aliquots of cells from the first two patients studied in Table 1 (nos. 1 and 2) and the first patient studied in Table 4 (no. 5) were used. The results obtained (Table 6) show no evidence of a negative effect of Ph+ cells on the ability of normal LTC-IC to be amplified in suspension cultures containing the same five-cytokine cocktail (FL, SF, IL-3, IL-6, and G-CSF) used in the described experiments previously. Conversely, the presence of CD34+CD38- cells from normal marrow had no salvaging effect on the concomitant rapid loss in vitro of Ph+LTC-IC activity.
View this table:
[in this window]
[in a new window]
|
Table 6.
The Presence of Ph+CD34+CD38- CML Cells Has No Effect on the Expansion of Normal LTC-IC in 10-Day Cocultures
|
|
| |
DISCUSSION |
The present experiments show that previously cryopreserved, normal (Ph-) LTC-IC isolated from the peripheral blood of some CML patients at diagnosis14 could be expanded several-fold when incubated for 10 days under highly defined culture conditions (Table 4), although the expansion was less than what we have seen in analogous cultures of CD34+CD38- cells isolated from the marrow of normal individuals.23,30 Further studies will be required to determine whether a reduced proliferative potential may be a generalized feature of circulating or mobilized LTC-IC relative to the normal marrow LTC-IC population or whether this is a unique feature of circulating Ph-LTC-IC in CML patients. The variable yields of expanded Ph-LTC-IC in culture suggest that there may be considerable heterogeneity in the numbers of functionally different subtypes of LTC-IC (or their precursors)22,32-34 that are spontaneously mobilized in different CML patients. Under the same culture conditions, Ph+LTC-IC were unable to maintain their functional state. This defective behavior of Ph+LTC-IC could be seen in cultures containing a variety of cytokine supplements (Tables 1 and 3) and occurred independent of whether or not normal LTC-IC were present (Table 6). In previous studies, we have shown that Ph+LTC-IC decrease 50-fold more rapidly than do normal LTC-IC, both under conditions used to initiate long-term cultures from bone marrow cells and when the cells are seeded onto preestablished marrow adherent layers.10,29 Under either of these conditions, which do not involve the provision of exogenous soluble cytokines, normal LTC-IC are maintained at input levels for 7 to 10 days, but do not expand. The fact that a marked loss of LTC-IC activity can also be demonstrated when Ph+LTC-IC are cultured in highly purified form and at low cell densities suggests that this abnormal behavior is intrinsically determined and not readily modulated by extracellular factors, including those involved in the interactions such cells have with stroma.35
The mechanism underlying the loss of LTC-IC activity exhibited by cultured Ph+ cells has not yet been determined. For example, whether the loss of this activity is associated with cell death or, alternatively, with a change in proliferative potential, acquisition of an ability to proliferate in methylcellulose and/or cytokine responsiveness are all questions that will need to be addressed in future studies. Some groups have obtained evidence to indicate that the BCR-ABL gene product can confer an increased resistance to the apoptotic response that is normally induced by factor deprivation36-38 and others have suggested that CML cells may be characterized by a tendency to differentiate prematurely.39,40 We have recently shown that circulating Ph+LTC-IC represent a rapidly cycling population, in contrast to the LTC-IC that circulate in normal individuals, or the Ph-LTC-IC that are sometimes also detectable in the blood of CML patients.41,42 In addition, we have recently shown that BCR-ABL mRNA is present at detectable levels in all types of primitive Ph+ cells regardless of their phenotype.43 Taken together, these findings support a model of CML in which the Ph+ stem cell has two linked features: (1) an intrinsically increased ability to remain alive and proliferate under conditions that may promote the apoptosis or quiescence of normal stem cells, and (2) a decreased probability of self-renewal, ie, an increased probability of differentiation.44 Such a model could account for a number of observations of the behavior of the leukemic clone in vivo. These include the relatively long average latent period (7 years) before Ph+ clones typically attain a size sufficient for the development of clinical symptoms of disease,45 the delayed relapses (after >5 years) that are occasionally seen in CML patients previously "cured" of their disease by an allogeneic bone marrow transplant,46 and the rapid but transient resurgence of predominantly Ph- hematopoiesis in patients given combination chemotherapy without a transplant.11,47
Finally, the present experiments draw attention to the possibility of using cell separation in combination with defined culture conditions to improve current culture-purging approaches to reducing the leukemic stem cell burden in CML autotransplants.27,28 A procedure that involves a significant reduction in the number of cells to be cultured and, hence, the volumes to be handled could greatly facilitate the development of more widely applicable, safer, and cheaper closed systems for the routine manipulation of such transplants. The added advantage of being able to simultaneously amplify the normal stem cell content of the graft while purging residual CML stem cells would also be particularly attractive for use in patients where the starting population of normal stem cells may be limiting13 or where a gene transfer procedure is envisaged.
| |
FOOTNOTES |
Submitted November 7, 1996;
accepted February 13, 1997.
Supported by grants from the National Cancer Institute of Canada (NCIC) with funds from the Terry Fox Run and the Canadian Cancer Society (to C.J.E., A.C.E, and M.J.B.) and a grant (No. J1034-MED) from the E. Schrödinger Foundation (to A.L.P.). C.J.E. is a Terry Fox Cancer Research Scientist of the NCIC supported by funds from the Terry Fox Run.
Address reprint requests to A.C. Eaves, MD, PhD, Terry Fox Laboratory, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
The excellent technical assistance of W. Dragowska and G. Thornbury for cell sorting and G. Shaw for performing the cytogenetic analyses is gratefully acknowledged. The authors also thank S. Clegg for expert assistance in preparing the manuscript; StemCell, Amgen (Thousand Oaks, CA), Immunex (Seattle, WA), and Sandoz (Basel, Switzerland) for generous gifts of reagents; and Dr P. Lansdorp for the 8G12-FITC antibody.
| |
REFERENCES |
1.
Raskind WH,
Fialkow PJ:
The use of cell markers in the study of human hematopoietic neoplasia.
Adv Cancer Res
49:127,
1987[Medline]
[Order article via Infotrieve]
2.
Groffen J,
Heisterkamp N:
The BCR/ABL hybrid gene.
Baillieres Clin Haematol
1:983,
1987[Medline]
[Order article via Infotrieve]
3.
Rowley JD:
A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
Nature
243:290,
1973[Medline]
[Order article via Infotrieve]
4.
Hariharan IK,
Adams JM,
Cory S:
BCR-ABL oncogene renders myeloid cell line factor independent: Potential autocrine mechanism in chronic myeloid leukemia.
Oncogene Res
3:387,
1988[Medline]
[Order article via Infotrieve]
5.
Daley GQ,
Van Etten RA,
Baltimore D:
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Science
247:824,
1990[Abstract/Free Full Text]
6.
Heisterkamp N,
Jenster G,
ten Hoeve J,
Zovich D,
Pattengale PK,
Groffen J:
Acute leukemia in bcr/abl transgenic mice.
Nature
344:251,
1990[Medline]
[Order article via Infotrieve]
7.
Elefanty AG,
Hariharan IK,
Cory S:
bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.
EMBO J
9:1069,
1990[Medline]
[Order article via Infotrieve]
8.
Kelliher MA,
McLaughlin J,
Witte ON,
Rosenberg N:
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Proc Natl Acad Sci USA
87:6649,
1990[Abstract/Free Full Text]
9.
Gishizky ML,
Johnson-White J,
Witte ON:
Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
Proc Natl Acad Sci USA
90:3755,
1993[Abstract/Free Full Text]
10.
Coulombel L,
Kalousek DK,
Eaves CJ,
Gupta CM,
Eaves AC:
Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
N Engl J Med
308:1493,
1983[Abstract]
11.
Goto T,
Nishikori M,
Arlin Z,
Gee T,
Kempin S,
Burchenal J,
Strife A,
Wisniewski D,
Lambek C,
Little C,
Jhanwar S,
Chaganti R,
Clarkson B:
Growth characteristics of leukemic and normal hematopoietic cells in Ph1+ chronic myelogenous leukemia and effects of intensive treatment.
Blood
59:793,
1982[Free Full Text]
12.
Talpaz M,
Kantarjian HM,
McCredie K:
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia.
N Engl J Med
314:1065,
1986[Abstract]
13.
Eaves C,
Udomsakdi C,
Cashman J,
Barnett M,
Eaves A:
The biology of normal and neoplastic stem cells in CML.
Leuk Lymphoma
11:245,
1993
14.
Petzer AL,
Eaves CJ,
Lansdorp PM,
Ponchio L,
Barnett MJ,
Eaves AC:
Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia.
Blood
88:2162,
1996[Abstract/Free Full Text]
15.
Carella AM,
Podesta M,
Frassoni F,
Raffo MR,
Pollicardo N,
Pungolino E,
Vimercati R,
Sessarego M,
Parodi C,
Rabitti C,
Ferrero R,
Benvenuto F,
Figari O,
Carlier P,
Levcasic G,
Valbonesi M,
Vitale V,
Giordano D,
Pierluigi D,
Nati S,
Guerracio A,
Rosso C,
Saglio G:
Collection of "normal" blood repopulating cells during early hematopoeietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Bone Marrow Transplant
12:267,
1993[Medline]
[Order article via Infotrieve]
16.
Sirard C,
Lapidot T,
Vormoor J,
Cashman JD,
Doedens M,
Murdoch B,
Jamal N,
Messner H,
Addey L,
Minden M,
Laraya P,
Keating A,
Eaves A,
Lansdorp PM,
Eaves CJ,
Dick JE:
Normal and leukemic SCID-repopulating cells (SRC) co-exist in the bone marrow and peripheral blood from CML patients in chronic phase while leukemic SRC are detected in blast crisis.
Blood
87:1539,
1996[Abstract/Free Full Text]
17.
Sutherland HJ,
Lansdorp PM,
Henkelman DH,
Eaves AC,
Eaves CJ:
Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers.
Proc Natl Acad Sci USA
87:3584,
1990[Abstract/Free Full Text]
18.
Kalousek DK,
Eaves CJ,
Eaves AC:
In-vitro cytogenetic studies of haemopoietic malignancies.
Cancer Surv
3:439,
1984
19.
Civin CI,
Strauss LC,
Brovall C,
Fackler MJ,
Schwartz JF,
Shaper JH:
Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells.
J Immunol
133:157,
1984[Abstract]
20.
Terstappen LWMM,
Huang S,
Safford M,
Lansdorp PM,
Loken MR:
Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells.
Blood
77:1218,
1991[Abstract/Free Full Text]
21.
Issaad C,
Croisille L,
Katz A,
Vainchenker W,
Coulombel L:
A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38- progenitor cells in long-term cultures and semisolid assays.
Blood
81:2916,
1993[Abstract/Free Full Text]
22.
Sauvageau G,
Lansdorp PM,
Eaves CJ,
Hogge DE,
Dragowska WH,
Reid DS,
Largman C,
Lawrence HJ,
Humphries RK:
Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells.
Proc Natl Acad Sci USA
91:12223,
1994[Abstract/Free Full Text]
23.
Petzer AL,
Hogge DE,
Lansdorp PM,
Reid DS,
Eaves CJ:
Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium.
Proc Natl Acad Sci USA
93:1470,
1996[Abstract/Free Full Text]
24.
Verfaillie CM,
Miller WJ,
Boylan K,
McGlave PB:
Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression.
Blood
79:1003,
1992[Abstract/Free Full Text]
25.
Udomsakdi C,
Eaves CJ,
Lansdorp PM,
Eaves AC:
Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia.
Blood
80:2522,
1992[Abstract/Free Full Text]
26.
Verfaillie CM,
Bhatia R,
Miller W,
Mortari F,
Roy V,
Burger S,
McCullough J,
Stieglbauer K,
Dewald G,
Heimfeld S,
Miller JS,
McGlave PB:
BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Blood
87:4770,
1996[Abstract/Free Full Text]
27.
Barnett MJ,
Eaves CJ,
Phillips GL,
Kalousek DK,
Klingemann H-G,
Lansdorp PM,
Reece DE,
Shepherd JD,
Shaw GJ,
Eaves AC:
Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture.
Bone Marrow Transplant
4:345,
1989[Medline]
[Order article via Infotrieve]
28.
Barnett MJ,
Eaves CJ,
Phillips GL,
Gascoyne RD,
Hogge DE,
Horsman DE,
Humphries RK,
Klingemann H-G,
Lansdorp PM,
Nantel SH,
Reece DE,
Shepherd JD,
Spinelli JJ,
Sutherland HJ,
Eaves AC:
Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study.
Blood
84:724,
1994[Abstract/Free Full Text]
29.
Udomsakdi C,
Eaves CJ,
Swolin B,
Reid DS,
Barnett MJ,
Eaves AC:
Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level.
Proc Natl Acad Sci USA
89:6192,
1992[Abstract/Free Full Text]
30.
Petzer AL,
Zandstra PW,
Piret JM,
Eaves CJ:
Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: Novel responses to flt3-ligand and thrombopoietin.
J Exp Med
183:2551,
1996[Abstract/Free Full Text]
31.
Hogge DE,
Lansdorp PM,
Reid D,
Gerhard B,
Eaves CJ:
Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulated factor.
Blood
88:3765,
1996[Abstract/Free Full Text]
32.
Sutherland HJ,
Eaves CJ,
Eaves AC,
Dragowska W,
Lansdorp PM:
Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro.
Blood
74:1563,
1989[Abstract/Free Full Text]
33.
Prosper F,
Stroncek D,
Verfaillie CM:
Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor.
Blood
88:2033,
1996[Abstract/Free Full Text]
34.
Hao QL,
Thiemann FT,
Petersen D,
Smogorzewska EM,
Crooks GM:
Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progentior population.
Blood
88:3306,
1996[Abstract/Free Full Text]
35.
Verfaillie C,
Hurley R,
Bhatia R,
McCarthy JB:
Role of bone marrow matrix in normal and abnormal hematopoiesis.
Crit Rev Oncol Hematol
16:201,
1994[Medline]
[Order article via Infotrieve]
36.
Evans CA,
Owen-Lynch J,
Whetton AD,
Dive C:
Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
Cancer Res
53:1735,
1993[Abstract/Free Full Text]
37.
Bedi A,
Zehnbauer BA,
Barber J,
Sharkis S,
Jones R:
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.
Blood
83:2038,
1994[Abstract/Free Full Text]
38.
Cortez D,
Kadlec L,
Pendergast AM:
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Mol Cell Biol
15:5531,
1995[Abstract]
39.
Strife A,
Lambek C,
Wisniewski D,
Wachter M,
Gulati SC,
Clarkson BD:
Discordant maturation as the primary biological defect in chronic myelogenous leukemia.
Cancer Res
48:1035,
1988[Abstract/Free Full Text]
40.
Fokas AS,
Keller JB,
Clarkson BD:
Mathematical model of granulocytopoiesis and chronic myelogenous leukemia.
Cancer Res
51:2084,
1991[Abstract/Free Full Text]
41.
Ponchio L,
Conneally E,
Eaves C:
Quantitation of the quiescent fraction of longterm culture-initiating cells (LTC-IC) in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro.
Blood
86:3314,
1995[Abstract/Free Full Text]
42. Ponchio L, Cashman J, Zoumbos N, Eaves CJ, Eaves A: Primitive CML cells show a deregulation of their cycling status both in vivo and in longterm cultures which is not normalized in the presence of interferon- . Blood 86:493a, 1995 (abstr, suppl 1)
43.
Maguer-Satta V,
Petzer AL,
Eaves AC,
Eaves CJ:
BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
Blood
88:1796,
1996[Abstract/Free Full Text]
44.
Eaves CJ,
Cashman JD,
Zoumbos NC,
Barnett MJ,
Eaves AC:
Biological strategies for the selective manipulation of normal and leukemic stem cells.
Stem Cells
11:109,
1993
45.
Heyssel R,
Brill AB,
Woodbury LA,
Nishimura ET,
Ghose T,
Hoshino T,
Yamasaki M:
Leukemia in Hiroshima atomic bomb survivors.
Blood
15:313,
1960[Abstract/Free Full Text]
46.
van Rhee F,
Lin F,
Cross NCP,
Reid CDL,
Lakhani AKV,
Szydlo RM,
Goldman JM:
Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia.
Bone Marrow Transplant
14:609,
1994[Medline]
[Order article via Infotrieve]
47.
Kantarjian HM,
Vellekoop L,
McCredie KB,
Keating MJ,
Hester J,
Smith T,
Barlogie B,
Trujillo J,
Freireich EJ:
Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.
J Clin Oncol
3:192,
1985[Abstract]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. James, F. Mazurier, S. Dupont, R. Chaligne, I. Lamrissi-Garcia, M. Tulliez, E. Lippert, F.-X. Mahon, J.-M. Pasquet, G. Etienne, et al.
The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
Blood,
September 15, 2008;
112(6):
2429 - 2438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Bowie, D. G. Kent, M. R. Copley, and C. J. Eaves
Steel factor responsiveness regulates the high self-renewal phenotype of fetal hematopoietic stem cells
Blood,
June 1, 2007;
109(11):
5043 - 5048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Jiang, K. M. Saw, A. Eaves, and C. Eaves
Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells
J Natl Cancer Inst,
May 2, 2007;
99(9):
680 - 693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Glimm, M. Schmidt, M. Fischer, K. Schwarzwaelder, M. Wissler, S. Klingenberg, C. Prinz, C. F. Waller, W. Lange, C. J. Eaves, et al.
Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients
Blood,
August 1, 2005;
106(3):
893 - 898.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ramaraj, H. Singh, N. Niu, S. Chu, M. Holtz, J. K. Yee, and R. Bhatia
Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors
Cancer Res.,
August 1, 2004;
64(15):
5322 - 5331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bartolovic, S. Balabanov, U. Hartmann, M. Komor, A. M. Boehmler, H.-J. Buhring, R. Mohle, D. Hoelzer, L. Kanz, W.-K. Hofmann, et al.
Inhibitory effect of imatinib on normal progenitor cells in vitro
Blood,
January 15, 2004;
103(2):
523 - 529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Strife, D. Wisniewski, C. Liu, C. L. Lambek, Z. Darzynkiewicz, R. T. Silver, and B. Clarkson
Direct Evidence That Bcr-Abl Tyrosine Kinase Activity Disrupts Normal Synergistic Interactions Between Kit Ligand and Cytokines in Primary Primitive Progenitor Cells
Mol. Cancer Res.,
January 1, 2003;
1(3):
176 - 185.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
W. H. Matsui, D. E. Gladstone, M. S. Vala, J. P. Barber, R. A. Brodsky, B. D. Smith, and R. J. Jones
The Role of Growth Factors in the Activity of Pharmacological Differentiation Agents
Cell Growth Differ.,
June 1, 2002;
13(6):
275 - 283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Holtz, M. L. Slovak, F. Zhang, C. L. Sawyers, S. J. Forman, and R. Bhatia
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation
Blood,
May 15, 2002;
99(10):
3792 - 3800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Luger, S. G. O'Brien, J. Ratajczak, M. Z. Ratajczak, R. Mick, E. A. Stadtmauer, P. C. Nowell, J. M. Goldman, and A. M. Gewirtz
Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study
Blood,
February 15, 2002;
99(4):
1150 - 1158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Holyoake, X. Jiang, H. G. Jorgensen, S. Graham, M. J. Alcorn, C. Laird, A. C. Eaves, and C. J. Eaves
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
Blood,
February 1, 2001;
97(3):
720 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Brummendorf, T. L. Holyoake, N. Rufer, M. J. Barnett, M. Schulzer, C. J. Eaves, A. C. Eaves, and P. M. Lansdorp
Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
Blood,
March 15, 2000;
95(6):
1883 - 1890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Engelhardt, K. Mackenzie, P. Drullinsky, R. T. Silver, and M. A. S. Moore
Telomerase Activity and Telomere Length in Acute and Chronic Leukemia, Pre- and Post-ex Vivo Culture
Cancer Res.,
February 1, 2000;
60(3):
610 - 617.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Holyoake, X. Jiang, C. Eaves, and A. Eaves
Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid Leukemia
Blood,
September 15, 1999;
94(6):
2056 - 2064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bennaceur-Griscelli, C. Tourino, B. Izac, W. Vainchenker, and L. Coulombel
Murine Stromal Cells Counteract the Loss of Long-Term Culture-Initiating Cell Potential Induced by Cytokines in CD34+CD38low/neg Human Bone Marrow Cells
Blood,
July 15, 1999;
94(2):
529 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Moore, D. N. Haylock, J.-P. Levesque, L. A. McDiarmid, L. M. Samels, L. B. To, P. J. Simmons, and T. P. Hughes
Stem Cell Factor as a Single Agent Induces Selective Proliferation of the Philadelphia Chromosome Positive Fraction of Chronic Myeloid Leukemia CD34+ Cells
Blood,
October 1, 1998;
92(7):
2461 - 2470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.C.Y. Wang, T. Lapidot, J.D. Cashman, M. Doedens, L. Addy, D.R. Sutherland, R. Nayar, P. Laraya, M. Minden, A. Keating, et al.
High Level Engraftment of NOD/SCID Mice by Primitive Normal and Leukemic Hematopoietic Cells From Patients With Chronic Myeloid Leukemia in Chronic Phase
Blood,
April 1, 1998;
91(7):
2406 - 2414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract